Nothing said here yet.
to join the conversation.
| MIGNONE ROBERTODirector | Sell | 367,600 | $14.4M | Fri, Sep 18 |
| Savage BrianInterim Chief Legal Officer | Sell | 4,503 | $174.2K | Fri, Sep 18 |
| Savage BrianInterim Chief Legal Officer | Sell | 2,525 | $98.8K | Fri, Sep 18 |
| Savage BrianInterim Chief Legal Officer | Sell | 314 | $12.2K | Fri, Sep 18 |
| Weiss AmirChief Accounting Officer | Sell | 6,945 | $261.2K | Fri, Aug 21 |
| Weiss AmirChief Accounting Officer | Sell | 2,500 | $94.1K | Fri, Aug 21 |
| Satchi-Fainaro RonitDirector | Sell | 415 | $15.5K | Fri, Aug 21 |
| Lippman EvanEVP, Business Development | Sell | 18,600 | $680.3K | Mon, Aug 17 |
| Alan Armstrong | Buy | $8.0K | Mon, Mar 30 | Tue, Jul 21 |
Teva's pivot from generics to branded drugs has succeeded, but keep an eye out for this potential headwind.
Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Teva Pharmaceutical Industries stock: why WELTRUZA’s FDA approval matters now Teva Pharmaceutical Industries (NYSE:TEVA) just secured U.S. FDA approval for WELTRUZA, a once monthly injectable olanzapine treatment for adult schizophrenia, with a special call…
Analysts say that duvakitug could be differentiated from other pipeline TL1A candidates as the race to market heats up.
Teva Pharmaceutical Industries' (TEVA) affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday
Teva Pharmaceutical stock rallied Friday on FDA approval for Weltruza. But is it already too late to invest in TEVA shares? Let’s find out!
Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
Hardman Johnston Global Advisors, an investment management firm, issued its Q3 2026 investor letter for the “Hardman Johnston International Equity Developed Markets Strategy”. The letter can be downloaded here.
Teva said it is debuting the drug to overcome adherence issues with an oral counterpart and improve symptom outcomes.